Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015 (2015), Article ID 179434, 8 pages
Research Article

Characterization of Clinical and Genetic Risk Factors Associated with Dyslipidemia after Kidney Transplantation

1Department of Urology, Akita University Graduate School of Medicine, Akita 010-8543, Japan
2Department of Pharmacy, Akita University Hospital, Akita 010-8543, Japan
3Center for Kidney Disease and Transplantation, Akita University Hospital, Akita 010-8543, Japan

Received 31 December 2014; Accepted 26 March 2015

Academic Editor: Mariann Harangi

Copyright © 2015 Kazuyuki Numakura et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


We determined the prevalence of dyslipidemia in a Japanese cohort of renal allograft recipients and investigated clinical and genetic characteristics associated with having the disease. In total, 126 patients that received renal allograft transplants between February 2002 and August 2011 were studied, of which 44 recipients (34.9%) were diagnosed with dyslipidemia at 1 year after transplantation. Three clinical factors were associated with a risk of having dyslipidemia: a higher prevalence of disease observed among female than male patients and treatment with high mycophenolate mofetil and prednisolone doses per body weight at 28 days after transplantation. The genetic association between dyslipidemia and 60 previously described genetic polymorphisms in 38 putative disease-associated genes was analyzed. The frequency of dyslipidemia was significantly higher in patients with the glucocorticoid receptor (NR3C1) Bcl1 G allele than in those with the CC genotype . A multivariate analysis revealed that the NR3C1 Bcl1 G allele was a significant risk factor for the prevalence of dyslipidemia (odds ratio = 4.6; 95% confidence interval = 1.8–12.2). These findings may aid in predicting a patient’s risk of developing dyslipidemia.